FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--ImmunSYS, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products, today announced that results from a proof of concept (PoC) study evaluating its proprietary immunotherapy platform, YourVaccxTM, for the treatment of patients with metastatic solid tumor cancers will be presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II being held June 22 – 24.
The poster (#6540) entitled, “Regression of metastatic cancer and abscopal effects following in situ vaccination by cryosurgical tumor cell lysis and intratumoral immunotherapy: A case series” will be presented by Gary Onik, M.D.
ImmunSYS’s abstract can be found at https://www.abstractsonline.com/pp8/#!/9045/presentation/7023.
Following the presentation, a copy of the poster will be posted on www.immunsys.com.
ImmunSYS, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with metastatic prostate cancer and other metastatic solid tumors.
ImmunSYS is committed to bringing life-changing treatments to patients with metastatic cancer. The Company’s platform technology, YourVaccx, empowers the immune system to generate a strong anticancer effect, potentially creating abscopal effects through the combination of cryosurgical cellular lysis and the intratumoral delivery of a proprietary triple-component immunotherapeutic drug that is in development.
The YourVaccx therapy has the potential to offer patients with metastatic solid tumors benefits over the existing standard of care. The company’s lead development program is the treatment of metastatic prostate cancer, followed by a pipeline of development programs for other metastatic solid tumors. For more information about the company and its programs, visit www.immunsys.com. Follow and connect with us on Twitter, Facebook, YouTube and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This news release contains forward-looking statements. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and other words and terms of similar meaning. The forward-looking statements contained in this news release include, but are not limited to, statements relating to future clinical results and the effectiveness of the company’s therapies. These forward-looking statements are subject to risks, uncertainties and other factors. Accordingly, actual results may differ significantly from those projected in the forward-looking statements contained herein. Readers should not place undue reliance on these forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company does not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.